Results 101 to 110 of about 4,504 (155)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients

Critical Care, 2019
Background The population pharmacokinetics of total and unbound posaconazole following intravenous administration has not yet been described for the critically ill patient population. The aim of this work was, therefore, to describe the total and unbound
Fekade B. Sime, Catherine J. Byrne, Suzanne Parker, Janine Stuart, Jenie Butler, Therese Starr, Saurabh Pandey, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts   +9 more
doaj   +1 more source

Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology, 2012
INTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.
Amir A Tahami Monfared, Amy K O’Sullivan, Coleman Rotstein, George Papadopoulos   +3 more
doaj   +1 more source

Efficacy and Safety Assessment of Antifungal Prophylaxis with Posaconazole Using Therapeutic Drug Monitoring in Pediatric Patients with Oncohematological Disorders—A Single-Centre Study

Journal of Fungi
Introduction: Posaconazole is recommended for prophylaxis in pediatric immunocompromised patients. Due to its variability in bioavailability and drug-to-drug interactions, EBMT recommends regimens based on therapeutic drug monitoring (TDM). Materials and
Karolina Liszka, Paweł Marschollek, Dawid Przystupski, Jowita Frączkiewicz, Monika Mielcarek-Siedziuk, Igor Olejnik, Zuzanna Gamrot, Natalia Haze, Agnieszka Kwella, Paulina Zalewska, Matylda Resztak, Marek Ussowicz, Krzysztof Kałwak   +12 more
doaj   +1 more source

Relevance of Timing for Determination of Posaconazole Plasma Concentrations

, 2011
For posaconazole, drug monitoring is suggested, but the relevance of timing for the determination of posaconazole concentration (PC) remains unclear.
Hartwig Klinker, Daniela Keller, Werner J. Heinz, Diana Schirmer, Anna Kuhn, Janina Zirkel, Ulrike Lenker   +6 more
core   +1 more source

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug–Drug Interaction Studies

Drug Design, Development and Therapy
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj  

Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations

, 2019
International audienceThe delayed-release tablet formulation of posaconazole (POS-tab) results in higher plasma POS trough concentrations (C min ) than the oral suspension (POS-susp), which raises the question of the utility of therapeutic drug ...
Weiss, Stéphanie, Thiebaut-Bertrand, Anne, Roustit, Matthieu, Brenier-Pinchart, Marie-Pierre, Gautier-Veyret, Elodie, Tonini, Julia, Bolcato, Léa, Cornet, Muriel, Stanke-Labesque, Françoise   +8 more
core   +1 more source

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML

Antimicrobial Agents and Chemotherapy
To determine midostaurin and posaconazole plasma concentrations and investigate adverse events (AEs) resembling drug-drug interactions (DDI) when both drugs were administered concomitantly during induction chemotherapy for acute myeloid leukemia (AML ...
Carolin S. Joisten, Sibylle C. Mellinghoff, Danila Seidel, Carsten Müller, Charlotte Müller-Ohrem, Karl-Anton Kreuzer, Lukas P. Frenzel, Florian Simon, Michael Hallek, Philipp Koehler, Oliver A. Cornely, Jannik Stemler   +11 more
doaj   +1 more source

Disseminated Fusariosis Occurring in Two Patients Despite Posaconazole Prophylaxis

, 2011
Posaconazole is widely used for prophylaxis against invasive fungal infections in patients undergoing myeloablative therapy. Disseminated fusariosis is a serious invasive mold infection in such patients. Preclinical and clinical studies indicate activity
Jennifer L. Holter, Hiral D. Parekh, Ronald A. Greenfield, Prithviraj Bose   +3 more
core   +1 more source

Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review

Frontiers in Pharmacology
BackgroundPosaconazole is a potent antifungal agent widely used to manage invasive fungal infections, especially in immunocompromised individuals.
Ruochen Qu, Ruochen Qu, Yan Liu, Yan Liu, Yan Zhao, Yan Zhao, Ziyi Wang, Ziyi Wang, Shizhao Yuan, Shuai Liu, Jing Yu, Jing Yu   +11 more
doaj   +1 more source

Chemical structures of posaconazole and fluconazole.

, 2013
Chemical structures of posaconazole and fluconazole.
Matthew P. Jacobson (174588), James H. McKerrow (113918), Christophe Guilbert (365836), Siegfried S. F. Leung (365835), Larissa M. Podust (145743), Chiung-Kuang Chen (145721)   +5 more
core   +1 more source